Currently Enrolling
Asthma
Phase 2b
Study ID: KT621-AS-202

Uncontrolled Moderate to Severe Eosinophilic Asthma

Sponsored by Kymera Therapeutics, Inc.

Official Study Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
Sponsor
Kymera Therapeutics, Inc.
Phase
Phase 2b
Indication
Uncontrolled Moderate to Severe Eosinophilic Asthma
Duration
Contact us for details
About This Study

Objective

To evaluate the efficacy of multiple doses of KT-621 compared to placebo in participants with uncontrolled moderate to severe eosinophilic asthma.

Who Can Participate

Key Eligibility Criteria

Below are the main inclusion and exclusion criteria for this study. The full eligibility assessment will be discussed with you by our research team during screening.

Key Inclusion Criteria

  • Adults aged ≥18 years
  • Physician-diagnosed asthma for ≥12 months
  • Moderate-to-severe asthma inadequately controlled despite standard therapy
  • Stable asthma background therapy prior to screening
  • Demonstrated airflow limitation on spirometry
  • Willing and able to comply with study procedures
  • Documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids and/or a hospitalization or emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to the Screening visit (V1)

Key Exclusion Criteria

  • Diagnosis of COPD or other significant chronic lung disease
  • Current smokers or significant smoking history (per protocol limits)
  • Recent asthma exacerbation requiring systemic corticosteroids
  • Use of biologic therapies within protocol-defined washout period
  • Clinically significant uncontrolled comorbidities
  • Active or chronic infections (e.g., TB, hepatitis, HIV)
  • Pregnant or breastfeeding
  • Known hypersensitivity to study drug or excipients
Get Started

Apply for this study

Fill out the form below to see if you qualify. Our research coordinators will contact you directly to discuss your eligibility — there's no obligation to participate.

Your information is kept confidential and only used for study eligibility purposes.

Research team discussing clinical study data in laboratory
Why Participate

Advancing research, one participant at a time.

Clinical trials depend on volunteers like you. By participating, you gain access to potential new treatments while helping researchers discover safer, more effective therapies for everyone.

  • Access to investigational treatments and expert medical care
  • Close monitoring by our experienced research team
  • Contribute to better treatments for future patients
  • Confidential — your information is protected at every step